Krystal Biotech (KRYS) Receivables (2023 - 2026)
Krystal Biotech (KRYS) posted quarterly Receivables of $138.7 million for Q2 2026, up 24.46% year-over-year from $111.4 million in Q2 2025, and up 9.19% on a QoQ basis from $127.0 million in Q1 2026.
Krystal Biotech (KRYS) Receivables (2023 - 2026) Analysis & Trends
Krystal Biotech has reported Receivables for 4 years, with the latest figure at $138.7 million in Q2 2026.
- Receivables for Q2 2026 came in at $138.7 million, up 24.46% year-over-year; the trailing twelve-month figure through Jun 2026 was $138.7 million (up 24.46% YoY), and the FY2025 annual result was $127.4 million, up 21.65% from the prior year.
- Receivables advanced to $138.7 million in Q2 2026, from $127.0 million in the prior quarter.
- Over five years, Receivables peaked at $138.7 million in Q2 2026 and troughed at $9.3 million in Q3 2023.
- A 4-year average of $99.9 million and a median of $104.7 million in 2024 frame the typical range for Receivables.
- The widest annual swing landed in 2024, when Receivables soared 944.42%; it then fell 1.38% in 2025.
- A 4-year view of Receivables shows it stood at $42.0 million in 2023, then soared by 149.16% to $104.7 million in 2024, then advanced by 21.65% to $127.4 million in 2025, then gained by 8.85% to $138.7 million in 2026.
- Per Business Quant data, the three most recent Receivables figures were $138.7 million in Q2 2026, $127.0 million in Q1 2026, and $127.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 138.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 138.70 Mn |
| Mar 31, 2026 | 127.02 Mn |
| Dec 31, 2025 | 127.40 Mn |
| Sep 30, 2025 | 129.63 Mn |
| Jun 30, 2025 | 111.40 Mn |
| Mar 31, 2025 | 103.30 Mn |
| Dec 31, 2024 | 104.75 Mn |
| Sep 30, 2024 | 97.30 Mn |
| Jun 30, 2024 | 103.24 Mn |
| Mar 31, 2024 | 104.75 Mn |
| Dec 31, 2023 | 42.04 Mn |
| Sep 30, 2023 | 9.32 Mn |